Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)
-
Published:2019-02
Issue:2
Volume:30
Page:161-165
-
ISSN:0923-7534
-
Container-title:Annals of Oncology
-
language:en
-
Short-container-title:Annals of Oncology
Author:
Peters S.ORCID,
Dafni U.,
Boyer M.,
De Ruysscher D.,
Faivre-Finn C.,
Felip E.,
Garrido P.,
Girard N.,
Guckenberger M.,
Haanen J.,
Le Pechoux C.,
Mornex F.,
Ozsahin M.,
Paz-Ares L.,
Planchard D.,
Raben D.,
Ramalingam S.,
Reck M.,
Smit E.,
Stahel R.,
Stenzinger A.,
Swanton C.,
Vallone S.,
Garassino M.C.
Subject
Oncology,Hematology
Cited by
59 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献